All In Biotech

Drug Trial Radar · NCT05456256

A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma

Phase II Trial of LP-300 in Combination With Carboplatin and Pemetrexed in Never Smoker Patients With Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment With Tyrosine Kinase Inhibitors (The HARMONIC Study)

Last checked: Nov 19, 2026Latest source record: May 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Mar 1, 2023

Primary completion

Dec 2026

Study completion Jun 2027

Sponsor

Lead sponsor
Lantern Pharma Inc.Industry
Sponsor type
Industry
First posted
Jul 13, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to determine clinical advantages for LP-300 in combination with carboplatin and pemetrexed in the never smoker patient population. The primary objectives of this study are to determine progression-free survival (PFS) and overall survival (OS) in the study-defined patient population when LP-300 is co-administered with the standard of care chemotherapy drugs carboplatin and pemetrexed compared to carboplatin and pemetrexed alone. This has been designed as a multicenter, open label, phase II trial with 90 patients to be enrolled in the United States.

Conditions

  • Adenocarcinoma of Lung
  • Carcinoma, Non-Small-Cell Lung

Interventions

  • LP-300Drug

    LP-300: 18.4 g/m2 by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. The number of treatment cycles will be determined by PI discretion.

  • PemetrexedDrug

    Pemetrexed: 500 mg/m2 by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. After completion of the 4 to 6 cycles, patients will have the option to continue pemetrexed maintenance therapy until disease progression, unacceptable toxicity, or patient preference/physician discretion. The number of treatment cycles will be determined by PI discretion.

  • CarboplatinDrug

    Carboplatin: area under the concentration-time curve 5 mg/mL per minute (AUC5) by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. The number of treatment cycles will be determined by PI discretion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: Through study completion, an average of 2 years
  2. Overall survival (OS)Time frame: Through study completion, an average of 2 years

Locations

16 sites in 3 countries. Site status is shown where the registry gives one.

  • Precision NextGen Oncology and Research Center

    Beverly Hills, California · Recruiting

  • Los Angeles Cancer Network

    Fountain Valley, California · Recruiting

  • Cancer and Blood Specialists Clinic

    Los Alamitos, California · Suspended

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania · Recruiting

  • UT Southwestern Medical Center

    Dallas, Texas · Recruiting

  • Inova Fairfax Hospital

    Fairfax, Virginia · Recruiting

  • Hokkaido Cancer Center

    Sapporo, Hokkaido, Japan · Active not recruiting

  • Kanagawa Cancer Center Hospital

    Yokohama, Kanagawa, Japan · Active not recruiting

  • Tohoku University Hospital

    Sendai, Miyagi, Japan · Active not recruiting

  • Okayama University Hospital

    Okayama, Okayama-ken, Japan · Active not recruiting

  • National Cancer Center Hospital

    Chuo-ku, Tokyo, Japan · Active not recruiting

  • National Taiwan University Hospital Hsin-Chu Branch

    Hsinchu, Taiwan · Recruiting

  • Chi Mei Medical Center

    Tainan, Taiwan · Recruiting

  • National Cheng Kung University Hospital

    Tainan, Taiwan · Recruiting

  • Taipei Veterans General Hospital

    Taipei, Taiwan · Recruiting

  • TriService General Hospital-Neihu Main Facility

    Taipei, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.